Sign In
Buy TSHA
$5.86
-0.0150 (-0.255%)
At Close: Jul 31, 2026
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:08pm, Friday, 01'st Mar 2024
DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
08:00am, Thursday, 29'th Feb 2024
REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company's request to initiate dose escalation; dosing of first patient in
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
04:01pm, Thursday, 15'th Feb 2024
DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializin
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 02'nd Feb 2024
DALLAS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t
7 Micro-Cap Stocks That Could Majorly Surprise Investors
02:23pm, Wednesday, 31'st Jan 2024
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable b
DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t
3 Growth Stocks That Could Go Parabolic in 2024
09:30am, Monday, 15'th Jan 2024
Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
08:00am, Wednesday, 10'th Jan 2024
Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Jan 2024
DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t
Which Penny Stocks Are Best? 3 That Insiders Like In November
02:03pm, Monday, 20'th Nov 2023
The world of penny stocks is interesting, offering the promise of significant returns for those willing to dive into this niche market. There aren't any guarantees that you'll immediately hit it big a
Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript
09:53pm, Tuesday, 14'th Nov 2023
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan
Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'
07:41pm, Friday, 03'rd Nov 2023
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting Rett Syndrome. The gene therapy market is projected
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
11:17am, Tuesday, 05'th Sep 2023
Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TSHA's 50-day simple moving average broke out abo
3 Small-Cap Stocks to Sell in September Before They Crash & Burn
03:04pm, Monday, 04'th Sep 2023
The market had a choppy August as traders digested the latest developments from a busy earnings season and a hawkish Federal Reserve. While the overall market is volatile, we've seen some large specul
Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript
11:13pm, Thursday, 11'th May 2023
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan - C
